Speaker illustration

Doctor Odd Erik Johansen

Boehringer Ingelheim, Hovik (Norway)

Odd Erik Johansen is a medical doctor working as a global clinical development lead at Nestlé Health Science in the area of cardiometabolism testing novel interventions to help control cardiovascular risk factors and brain health. Prior to joining Nestlé Health Science, he worked at Boehringer Ingelheim, where he was the medical lead for several cardiovascular outcome trials over the last decade (EMPA-REG OUTCOME®, CAROLINA® and CARMELINA®) and at a cardiology/endocrinology hospital department in Norway; where he still is affiliated as a post-doctoral researcher and is supervising PhD candidates. He obtained his MD from the University of Tromsø, Norway (1999) and his PhD in Cardiovascular Diabetology from University of Oslo, Norway (2007). He has given numerous oral and poster presentations at scientific meetings (including ADA, EASD, AHA, ASN, Obesity Week) and published > 100 peer-reviewed papers in the field including in N Engl J Med, JAMA, Diabetes Care, Eur Heart J.

Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex and hypertension in patients with T2DM and high CV risk: EMPA-reg outcome.

Event: ESC Congress 2017

Topic: Drug therapy

Session: Optimising cardiovascular pharmacotherapy

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb